Related Experiment Video
Updated: Jun 3, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
Promising emerging therapies for multiple sclerosis
1Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AN, UK. g.giovannoni@qmul.ac.uk
Abstract:
Until recently, interferon beta and glatiramer acetate were the only licensed disease-modifying therapies for relapsing forms of multiple sclerosis. These agents have a modest effect on reducing relapse rates. The licensing of two more effective agents, mitoxantrone and natalizumab, provided alternatives. These agents are associated with potentially life-threatening or serious side effects. In addition, none of these licensed agents has been shown to be effective in primary progressive MS. There is a large unmet need, with several promising new therapies in the pipeline. This article reviews the proposed mechanisms of action of the anticipated treatments, their efficacy, and risks associated with their use.
Related Concept Videos
Multiple Sclerosis l: Introduction
Microorganisms in Medicine and Therapeutics
Satellite Stem Cells and Muscular Dystrophy

